

MAILED
MAY 20 2002
PATENT

MILBANK, TWEED, HADLEY & McCLOY LLP

SERIAL NO. 09/474,677
ATTORNEY DOCKET NO. 36325-00600

1644

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Yash P. Sharma

Art Unit : 1644

Serial No. : 09/474,677

Examiner : Ronald B. Schwadron

Filed : December 29, 1999

Title : TREATMENT AND PREVENTION OF HIV AND OTHER VIRAL INFECTIONS

U.S. Patent and Trademark Office

Box Sequence

Washington, DC 20231

RECEIVED

MAY 22 2002

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR
AMINO ACID SEQUENCE DISCLOSURES

TECH CENTER 1600/2901

Dear Sir:

Responsive to the Notice dated April 10, 2002, and in accordance with 37 CFR 1.821 - 1.825, Applicant submits herewith the following.

1. A paper copy of a Sequence Listing for insertion into the Application as filed at the end of the Specification and prior to the Claims.
2. A copy of the Sequence Listing in computer readable form.
3. Amendment.
4. A statement in support of the filing and submission of a Sequence Listing in accordance with 37 CFR 1.821 - 1.825.
5. Notice to comply with requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures.

COPY OF PAPERS
ORIGINALLY FILED

Applicant requests favorable consideration and entry of the Sequence Listing submitted herewith and further and favorable processing of the present Application.

Date: May 9, 2002

Respectfully submitted,

W. Jackson Matney, Jr.
W. Jackson Matney, Jr.

Reg. No. 39,292

Milbank, Tweed, Hadley & McCloy LLP
International Square Building
1825 Eye Street, N.W.
Washington, DC 20006
Telephone: (202) 835-7500
Facsimile: (202) 835-7586

Date of Deposit: May 9, 2002

I hereby certify under 37 C.F.R. § 1.8 that this correspondence is being deposited with the United States Postal Service on the date indicated above with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, DC 20231.

Karen L. Hudson

Karen L. Hudson

011
MAY 20 2002
PATENT

MILBANK, TWEED, HADLEY & McCLOY LLP

SERIAL NO. 09/474,677
ATTORNEY DOCKET NO. 36325-00600

8/A.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Yash P. Sharma
Serial No. : 09/474,677
Filed : December 29, 1999
Title : TREATMENT AND PREVENTION OF HIV AND OTHER VIRAL INFECTIONS

Art Unit : 1644
Examiner : Ronald B. Schwadron

Assistant Commissioner for Patents
Washington, DC 20231

AMENDMENT

RECEIVED

MAY 22 2002

TECH CENTER 1600/2900

Sir:

In accordance with 37 CFR 1.821 - 1.825, please amend the above-identified Application

as follows:

COPY OF PAPERS
ORIGINALLY FILED

In the Specification

Please insert the sequence listing into the Application at the end of the Specification and
prior to the Claims.

REMARKS

The foregoing amendment is submitted in order to enter the sequence listing into the
Application.

Applicants request favorable consideration and entry of the Amendment and Sequence
Listing submitted herewith and further and favorable processing of the present Application.

Respectfully submitted,

Date:

May 9, 2002

W. Jackson Matney, Jr.
W. Jackson Matney, Jr.
Reg. No. 39,292

Milbank, Tweed, Hadley & McCloy LLP
International Square Building
1825 Eye Street, N.W.
Washington, DC 20006
Telephone: (202) 835-7500
Facsimile: (202) 835-7586

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Yash P. Sharma
Serial No. : 09/474,677
Filed : December 29, 1999
Title : TREATMENT AND PREVENTION OF HIV AND OTHER VIRAL INFECTIONS

Art Unit : 1644
Examiner : Ronald B. Schwadron

Assistant Commissioner for Patents
Washington, DC 20231

RECEIVED

MAY 22 2002

TECH CENTER 1600/2900

STATEMENT IN SUPPORT OF THE FILING/SUBMISSION OF A
NUCLEOTIDE/AMINO ACID SEQUENCE LISTING IN
ACCORDANCE WITH 37 CFR §§ 1.821 - 1.825

Dear Sir:

COPY OF PAPERS
ORIGINALLY FILED

W. Jackson Matney, Jr., attorney of record, hereby states as follows:

1. I hereby state that the content of the paper and computer readable copies of the Sequence Listing submitted in accordance with 37 CFR § 1.821(c) and (e), respectively are the same.
2. I hereby state that the submission, filed in accordance with 37 CFR § 1.821(g) herein does not include new matter.
3. I hereby declare that all statements made herein of the undersigned's own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18 of the U.S. Code, Section 1001 and that such willful false statements may jeopardize the validity of this Application or any patent issuing thereon.

Date:

May 9, 2002

W. Jackson Matney, Jr.
W. Jackson Matney, Jr.
Reg. No. 39,292



COPY OF PAPERS
ORIGINALLY FILED

Application No.: 09/474677

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: _____

RECEIVED

MAY 22 2002

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

TECH CENTER 1600/2900